Journey Medical Corporation (DERM) Q1 FY26 Earnings Call

Amrosi is scaling with improving reimbursement, but quality formulary coverage remains the key conversion catalyst.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-13
Length41 minutes
EPS$-0.08
EPS consensus$-0.07
Revenue$16.0M
Revenue consensus$15.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All DERM earnings ยท Back to DERM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.